Abstract: The present disclosure provides ?-diketones or analogs thereof, that activate Wnt/?-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.

Abstract: This document relates to materials and methods for generating early flowering oilseed (e.g., pennycress) plants. For example, oilseed plants (e.g., modified oilseed plants) having one or more modifications in a polypeptide involved in early flowering (e.g., early flowering six (ELF6)), as well as materials and methods for making and using early flowering oilseed plants are provided.

Abstract: Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: 6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: 4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: A closed suction system module is provided. In one embodiment, the closed suction system module includes a coupling member configured to couple to a suction port of a multi-port manifold or endotracheal tube adapter (e.g., dual-port or tri-port adapter). In one embodiment, the closed suction system module includes a suction catheter configured to clean the interior surfaces of body-inserted tubes or artificial airways (alone or in addition to suctioning natural airways or portions of the respiratory tract or other body lumens). The suction catheter may include a cleaning portion at a distal portion of the suction catheter (e.g., near the distal end or tip of the suction catheter). In some embodiments, the cleaning portion includes at least one expandable cleaning member (e.g., balloon, sleeve, wiper).

Abstract: Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: 4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: A forming belt for use in making a nonwoven substrate. The forming belt includes a first surface defining a plane of the first surface and an axis parallel to a longitudinal direction corresponding to a machine direction when in use. A plurality of discrete belt patterns can be ordered in sequential relationship with respect to the longitudinal direction. At least a majority of the plurality of discrete belt patterns can include a discrete belt pattern overall area, a first forming zone having a first pattern of three-dimensional raised elements extending outwardly from the plane of the first surface and a second forming zone having a second pattern of three-dimensional raised elements extending outwardly from the plane of the first surface. The first forming zone can have a first air permeability value and the second forming zone can have a second air permeability value. The first air permeability value can be different from the second air permeability value.

Abstract: Disclosed herein are methods and systems for integrating an enterprise's structured and unstructured data to provide users and enterprise applications with efficient and intelligent access to that data. In accordance with exemplary embodiments, the generation of classification information about unstructured data can be hardware-accelerated by processing streaming unstructured data through a reconfigurable logic device, a graphics processor unit (GPU), or chip multi-processor (CMP) to generate the classification metadata about the unstructured data.

Abstract: 4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: Systems and methods for magnetic field-dependent relaxometry using magnetic resonance imaging (“MRI”] are provided. Relaxation parameters, including longitudinal relaxation time (“T1”) and transverse relaxation time (“T2”), are estimated from magnetic resonance signal data acquired at multiple different magnetic field strengths using the same MRI system. By measuring these relaxation parameters as a function of magnetic field strength, T1 dispersion data, T2 dispersion data, or both, are generated. Based on this dispersion data, quantitative physiological parameters can be estimated. As one example, iron content can be estimated from T2 dispersion data.

Abstract: Generic shadowing allows a shadowing device in a process plant to automatically discover, without pre-configuration or pre-definition, and without the use of a configuration tool, source control objects that are hosted at other devices and that are to be shadowed. Source control objects may utilize any data type, format, structure, language, etc. The shadowing device includes a shadow manager and a set of primitive components defining simple data types that are utilized to discover the configurations/definitions and data types of source control objects, and includes a shadow library in which signatures of discovered source control objects are stored. Signatures are instantiated and used by the shadowing device to provide dynamic data to recipient devices, applications, and/or control objects in the process control system, where the dynamic data is a mirror of data that is observed first-hand by the source control objects during their on-line operations at their host devices.

Abstract: The present invention is a photochromic eyewear lens product comprising photochromics material(s) and selective filtering agent(s) that selectively attenuate a portion of the blue light spectral region between 400 nm and 500 nm. The selective attenuation preferably comprises a maximum reduction in transmittance in the filtered region of about 10-25% T relative to at least one adjacent spectral region when the lens product is in the rest state, and a maximum reduction in transmittance that is measurably less than the transmittance of at least one adjacent region of the visible spectrum when the lens product has darkened in the activated state.

Abstract: Improvements to an electrical junction box is disclosed. The junction box is configured with integrated connections in the back of the junction box. Switches and outlets have tabs in specific locations that align with the desired integrated connections to provide the desired function. All of the outlets and switches align parallel with the back and front of the junction box. The junction box is configurable to accept a single switch, dimmer switch, 3-way or outlet to many more than one function. In addition, the function of a junction box can be easily changed as long as the wiring has been connected to the new junction box. Installation and changes can be made in seconds instead of minutes. The depth of the internal distribution receptacle is adjustable within the adjustable electrical box to accommodate the thickness of the outlet or switch.

Abstract: A respiratory mask for continuous positive airway pressure treatment includes a cushion adapted to be positioned against the face of a patient. The cushion is configured in a gasket arrangement around an entrance to the airways of the patient. The cushion is constructed from a polyurethane foam and has a thickness of greater than about 5 mm.

Abstract: A center section/motor sub-assembly for use in a hydrostatic transmission includes a center section having a pump running face for interfacing with a pump, and a motor running face for interfacing with a motor. The center section and the motor are configured for the hydraulic separating forces of the motor to be reacted only into the center section. The center section has two internal passages between pump kidney ports and motor kidney port, and the motor kidney ports are raised in elevation relative to the pump kidney ports. The internal passages run parallel to each other as they rise in elevation. A hydrostatic transmission includes the sub-assembly enclosed by a housing, in combination with a pump and output shaft assembly. For installation, the output shaft assembly is configured as a separate component from the sub-assembly of the center section and the motor.

Abstract: 6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

Abstract: 4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.